Nicox SA, a French ophthalmology company, announced a significant milestone in its development of NCX 470, a novel eye drop aimed at treating open-angle glaucoma and ocular hypertension. Following a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company confirmed that it received positive feedback on its plans for submitting the NDA, which is anticipated to be filed by summer 2026.
FDA Meeting Validates NCX 470 Development Strategy
On February 16, 2026, Nicox revealed that the FDA's written feedback supported the current data package and the proposed format for the NDA application. This validation is crucial for Nicox, as it indicates that the FDA finds the existing clinical data satisfactory for submission. During the meeting, the agency did request additional pharmacokinetic data, which will be collected from a small cohort of patients in an ongoing study in Japan. Importantly, this additional data will not delay the planned NDA submission timeline.
Doug Hubatsch, EVP and Chief Scientific Officer of Nicox, noted, "The productive and collaborative pre-NDA meeting with the FDA was conducted with our partner Kowa. The outcome supports the finalization of our registration dossier, which includes positive results from two Phase 3 studies, and facilitates proceeding with the NDA submission." This is a pivotal step in the regulatory process for NCX 470, and it emphasizes the collaboration between Nicox and Kowa, which holds global rights for the product, except in select Asian markets.
Clinical Efficacy of NCX 470 Demonstrated in Studies
NCX 470, a unique formulation of bimatoprost that donates nitric oxide, has shown promising results in clinical trials aimed at lowering intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma or ocular hypertension. According to data from two Phase 3 studies, NCX 470 was able to reduce IOP by as much as 10 mmHg, a significant improvement that could enhance treatment options for patients suffering from these conditions. The innovative approach of combining bimatoprost with nitric oxide aims to provide better efficacy than current treatments on the market.
In addition to the U.S. NDA, plans are in place for further submissions in other markets. Nicox expects to submit an NDA in China shortly after the U.S. submission, expanding the potential reach of NCX 470 and its benefits. This strategy illustrates Nicox's commitment to making this innovative treatment available to a broader patient population.
Financial Implications and Future Milestones
With the NDA submission on track for summer 2026, Nicox is set to receive a milestone payment from Kowa upon the submission of the NDA. The company's financial outlook is bolstered by the potential for regulatory and sales milestones, along with royalties from worldwide sales of NCX 470. Kowa and Ocumension Therapeutics, which holds rights in China, South Korea, and Southeast Asia, are responsible for all regulatory and commercialization costs associated with NCX 470, further minimizing financial risks for Nicox.
Looking ahead, the timeline for NCX 470 includes a Phase 3 clinical program initiation in Japan, expected to begin in the summer of 2025. These developments indicate a robust pipeline for Nicox as they advance their portfolio of ocular therapies, with NCX 470 leading the way.
About Nicox and Its Vision for Ocular Health
Founded in Sophia Antipolis, France, Nicox SA is dedicated to developing innovative solutions that aim to improve ocular health and preserve vision. The company's lead product, NCX 470, exemplifies its commitment to advancing treatment options for patients with glaucoma and ocular hypertension. Beyond NCX 470, Nicox is also engaged in preclinical research on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, further diversifying its pipeline.
As the company prepares for the upcoming submission of NCX 470 to the FDA, the positive feedback from the pre-NDA meeting represents not only a vote of confidence in the drug's development but also signifies Nicox's potential to make meaningful contributions to the field of ophthalmology. With multiple milestones on the horizon, the company is poised to enhance its presence in the global market.